AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04435483
Drug: Acalabrutinib Treatment A
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
Trial: NCT04435483
Drug: Acalabrutinib Treatment B
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
Trial: NCT04435483
Drug: Acalabrutinib Treatment C
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
Trial: NCT03414658
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: work by interfering with cell division, which leaves the tumor unable to grow and spread
Trial: NCT03414658
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
Trial: NCT03414658
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
Trial: NCT03414658
Drug: Utomilumab
RxNorm normalized name: Utomilumab
DrugBank: Utomilumab (DB15113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
Trial: NCT00967317
Drug: Auris-Sedina
RxNorm normalized name: Ba-302 conjugated to monomethyl auristatin e
DrugBank: Ozuriftamab vedotin (DB17422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor.
Trial: NCT01981837
Drug: ALN-TTRSC (revusiran) for subcutaneous administration
RxNorm normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02534311
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
Trial: NCT00360698
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One daily injection at bedtime
Trial: NCT00360698
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At same dosage as during the run-in period
Trial: NCT00360698
Drug: Insulin Glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One bolus given before the main meal
Trial: NCT00360698
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At same dosage as during the run-in period
Trial: NCT05255575
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive ertapenem therapy.
Trial: NCT03082846
Drug: Temozolomide chemotherapy
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
Trial: NCT04088032
Drug: Abemaciclib, durvalumab and aromatase inhibitor
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
Trial: NCT00251459
Drug: rhuFab V2 (ranibizumab)
RxNorm normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03991936
Drug: Triamcinolone Acetonide 2.5 mg/mL
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/mL intralesional injection
Trial: NCT03991936
Drug: Triamcinolone Acetonide 5.0 mg/mL
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.0 mg/mL intralesional injection
Trial: NCT03991936
Drug: Triamcinolone Acetonide 7.5 mg/mL
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 mg/mL intralesional injection
Trial: NCT03991936
Drug: Triamcinolone Acetonide 10 mg/mL
RxNorm normalized name: triamcinolone acetonide 10 MG/ML
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/mL intralesional injection
Trial: NCT00269685
Drug: vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01877005
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00064363
Drug: talampanel
RxNorm normalized name: Talampanel
DrugBank: Talampanel (DB04982)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02365805
Drug: Docetaxel + Ciclofosfamide
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
Trial: NCT00728195
Drug: JNJ-37822681
RxNorm normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
Trial: NCT00728195
Drug: JNJ-37822681
RxNorm normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
Trial: NCT00728195
Drug: JNJ-37822681
RxNorm normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
Trial: NCT00728195
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
Trial: NCT03745989
Drug: MK-8353
RxNorm normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
Trial: NCT03745989
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
Trial: NCT03883581
Drug: dextromethorphan HBr and quinidine sulfate
RxNorm normalized name: dextromethorphan hydrobromide / quinidine sulfate Pill
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
Trial: NCT02356913
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01015404
Drug: Trafermin
RxNorm normalized name: trafermin
DrugBank: Trafermin (DB06244)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Administered to the bone defect during flap operation
Trial: NCT03073369
Drug: Ergocalciferol 50000 UNT
RxNorm normalized name: ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Ergocalciferol 50000 IU once daily for 6 weeks
Trial: NCT00287755
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
Trial: NCT02367859
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03189329
Drug: 2% lidocaine hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
Trial: NCT02367859
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03189329
Drug: 0.5% levobupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
Trial: NCT00413777
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
Trial: NCT01808196
Drug: Losartan Potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
Trial: NCT03332459
Drug: Lumicitabine
RxNorm normalized name: Lumicitabine
DrugBank: Lumicitabine (DB14808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Trial: NCT00362778
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous continuous insulin infusion for 48 hours
Trial: NCT01832467
Drug: cetuximab-containing chemotherapy
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02354235
Drug: Teneligliptin
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02354235
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00939341
Drug: Symbicort (Budesonide/Formoterol)
RxNorm normalized name: budesonide / formoterol Metered Dose Inhaler [Symbicort]
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
Trial: NCT00135408
Drug: Ipilimumab+ Placebo
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
Trial: NCT00135408
Drug: Ipilimumab+ Budesonide
RxNorm normalized name: Ipilimumab
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
Trial: NCT02844322
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
Trial: NCT02844322
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
Trial: NCT04614636
Drug: FT538
RxNorm normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
Trial: NCT04614636
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lympho-conditioning Agent
Trial: NCT02186275
Drug: Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Weight at inclusion \< 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~* Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.
Trial: NCT02280096
Drug: 4-aminopyridine
RxNorm normalized name: 4-aminopyridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
Trial: NCT02186275
Drug: Vitamin D3 800 UI/day then 800 UI/day
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Weight \< 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~* Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance
Trial: NCT04614636
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal Antibody, CD38, Anti-CD38
Trial: NCT02952885
Drug: Pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
Trial: NCT04614636
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal Antibody
Trial: NCT01863706
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400µg oral misoprostol
Trial: NCT01863706
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 IU Oxytocin
Trial: NCT00060151
Drug: pazopanib hydrochloride
RxNorm normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04802928
Drug: Isoniazid 300 milligram
RxNorm normalized name: Product containing precisely isoniazid 300 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets 150 milligram b.i.d.
Trial: NCT01948518
Drug: Oral sildenafil 20 mg
RxNorm normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
Trial: NCT00116012
Drug: rNAPc2
RxNorm normalized name: rNAPc2
DrugBank: Anpocogin (DB06552)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02919761
Drug: Acthar Gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 Units Acthar Gel per 1 mL for subcutaneous injection
Trial: NCT02210728
Drug: methylphenidate or amphetamine product
RxNorm normalized name: amphetamine Oral Product
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
Trial: NCT02967640
Drug: Ketalar
RxNorm normalized name: Ketalar
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
Trial: NCT01037140
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral cholecalciferol tablets of 175 micrograms daily for 6 months
Trial: NCT00676728
Drug: JNJ-26481585
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
Trial: NCT01740713
Drug: Deferiprone, dose level 1
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a solution at 80 mg/mL will be administered orally
Trial: NCT02282085
Drug: Aripiprazole Once-Monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04094896
Drug: TCHP
RxNorm normalized name: Trastuzumab, Carboplatin, Docetaxel, and Pertuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
Trial: NCT02039726
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 or 30 mg quizartinib tablets administered orally once daily
Trial: NCT02865928
Drug: Bupivicaine HCl
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided serratus plane block with bupivicaine
Trial: NCT01740713
Drug: Deferiprone, dose level 2
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a solution at 80 mg/mL will be administered orally
Trial: NCT01740713
Drug: Deferiprone, dose level 3
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a solution at 80 mg/mL will be administered orally
Trial: NCT00712335
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DPI 250 mcg BID for 3 weeks
Trial: NCT00712335
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO 10 mg QHS for 3 weeks
Trial: NCT00712335
Drug: Salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DPI 50mg BID for 3 weeks
Trial: NCT00855686
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg once daily oral dose
Trial: NCT02448095
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation of tolerability and safety profiles